Abstract OT1-08-03: Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence
Year: 2020
Type: conference-abstract
Source: Cancer Research
Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Unimed Medical Institute, Vall d'Hebron Institute of Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, National Taiwan University Hospital, Asan Medical Center, University of Chicago, University of Kansas Medical Center, University of California San Diego, Moores Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3006022360